Bone Biologics Corporation (BBLG)

Bone Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3.33	3.03	7.54	6.68	-
Cash & Short-Term Investments	3.33	3.03	7.54	6.68	-
Cash Growth	9.87%	-59.85%	12.93%	-	-
Prepaid Expenses	0.28	0.38	0.38	-	-
Other Current Assets	0.26	0.33	0.58	-	-
Total Current Assets	3.86	3.74	8.5	6.68	-
Total Assets	3.86	3.74	8.5	6.68	-
Accounts Payable	0.37	0.36	0.1	0.1	0.47
Accrued Expenses	-	-	-	-	1.5
Short-Term Debt	-	-	-	-	2.72
Current Portion of Long-Term Debt	-	-	-	-	9
Other Current Liabilities	0	0.47	2.44	-	-
Total Current Liabilities	0.38	0.83	2.55	0.1	13.69
Total Liabilities	0.38	0.83	2.55	0.1	13.69
Common Stock	0	0	0	0.01	0.01
Additional Paid-In Capital	88.5	83.81	77.91	77.04	55.16
Retained Earnings	-85.02	-80.91	-71.96	-70.48	-68.86
Shareholders' Equity	3.48	2.91	5.95	6.58	-13.69
Total Liabilities & Equity	3.86	3.74	8.5	6.68	-
Total Debt	-	-	-	-	11.72
Net Cash (Debt)	3.33	3.03	7.54	6.68	-11.72
Net Cash Growth	9.87%	-59.85%	12.93%	-	-
Net Cash Per Share	2.19	11.50	158.18	154.78	-229.24
Filing Date Shares Outstanding	3.27	0.53	0.07	0.04	0.05
Total Common Shares Outstanding	2.95	0.53	0.06	0.04	0.05
Working Capital	3.48	2.91	5.95	6.58	-13.69
Book Value Per Share	1.18	5.44	93.28	152.47	-267.75
Tangible Book Value	3.48	2.91	5.95	6.58	-13.69
Tangible Book Value Per Share	1.18	5.44	93.28	152.47	-267.75

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q